Please type a plus sign (+) incide this tox → +

PTO/SB/68A (10-96
Approved for use through 10/31/99. OMB 0851-0031
Internal and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Inder the Pap	erwork Reduction Act of Substitute for		e required to respond to a collection of information un IPTO	less it contains a valid CMB control number	Patent and Trademark Office: U.S. DEPARTMENT OF COMMERC	
				Complete if Known		
	STA	TEMEN	ON DISCLOSURE IT BY APPLICANT y sheets as necessary)	Application Number	09/709,045	
	(ase as many shoots as necessary)			Filing Date	November 10, 2000	
				First Named Inventor	M. Rigdon Lentz	
				Group Art Unit	1647	
				Examiner Name	Lorraine Spector	
Sheet	1	of	2	Attorney Docket Number	LEN 102	

			U.S. PATENT DOCUME	NTS	
Examiner Initials*	Cite No.1	US Patent Document Number Kind Code (if know	Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	Ī	5,621,077	Novick, et al.	04-15-1997	
		5,792,845	O'Reilly, et al.	08-11-1998	
		6,824,986	Finkelman, et al.	11-30-2004	
		7,196,070	Sukumar	03-27-2007	

FOREIGN PATENT DOCUMENTS Foreign Patent Document Name of Patentee or Date of Publication of Pages, Columns, Lines, Where Initials* Applicant of Cited Document Cited Document MM-Relevant Passages or Relevant DD-YYYY Figures Appear Office. Number* Kind Code (if known) 01-24-1991 WO 9100742 Giri & Horuk

Examiner's	Date Considered	
Signature		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique dealing designation number ² Sea attached Kinds of U.S. Palant Documents. ² Einer Office that issued the document, by the Vocider code (WIPO Standard STS), ² For Jacopase patent documents, the indication of the parent of the region of the Emperor must proceed the self-att number of the patent document. ³ Undir of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴ Applicant to place a check mark here if English language Translation is attaching the self-attached the self-

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete his form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SKND FESS OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent Washington. DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CMW/

PTO/SB/08A (10-96 Approved for use through 10/31/89. CMB 0551-0031 +

					Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE		
inder the Paperw	ork Reduction Act o	f 1995, no persons	are required to respond to a collection of information ur	nless it contains a valid OMB control number	7		
\$	Substitute for	r form 1449	VPTO	Complete if Known			
		ATEME	TION DISCLOSURE NT BY APPLICANT nv sheets as necessary)	Application Number	09/709,045		
(use as many sheets as necessary)	Filing Date	November 10, 2000					
				First Named Inventor	M. Rigdon Lentz		
				Group Art Unit	1647		
				Examiner Name	Lorraine Spector		
Sheet	2	of	2	Attorney Docket Number	LEN 102		

OTHER ART. NON PATENT LITERATURE DOCUMENTS

		OTHER ART NON PATENT LITERATURE DOCUMENTS	
xaminer's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T2
		DUMMER, "Circulating interleukin-2 receptors are a group of multimeric proteins with immunoreactivity for interleukin-2 receptor alpha, beta, and gamma chains", <i>J. Interferon Cytokine Res.</i> , 16(4):315-320 (1996).	
		K.A. FITZGERALD, et al., Cytokine Facts Book Second Edition, Academic Press New York, pages 71 and 272 (2001).	_
		LOTEM, et al., "Hematopoletic cytokines inhibit apoptosis induced by transforming growth factor beta 1 and cancer chemotherapy compounds in myeloid leukemic cells", <i>Blood</i> , 80(7):1750-1757 (1992).	
		NOVICK, "Soluble cytokine receptors are present in normal human urine", J. Exp. Med., 170(4):1409-1414 (1989).	-
		YOUNG, et al., "Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34+ natural suppressor cells", International J. Cancer, 74(1):69-74 (1997).	
			_
			L
			L

ALL BEFFRENCES CONSIDERED EXCEPT WHERE LINED THROUGH JCMW/

Examiner's /Cherie M. Woodward/ Dat	ate Considered	11/08/2011

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ¹ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¹ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ¹ Kind of document by the appropriate symbols as indicated on the document not will for jossible. ¹ Replacent to place a check met English inanjuage. Translation is attached.